-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, support policies for the centralized procurement of traditional Chinese medicine, traditional Chinese medicine formula granules, and medical insurance payment have been frequently issued at the national level.
Affected by this, the market space of traditional Chinese medicine is being further opened up.
According to analysis and prediction, the traditional Chinese medicine market will exceed 1 trillion yuan in 2024.
The prospects are very promising
.
The enthusiasm for the research and development of innovative traditional Chinese medicine drugs is high, and a large number of enterprises will benefit
.
It is understood that with the support of a series of favorable policies, both the number of applications and the number of approvals for innovative Chinese medicines in China have increased significantly
.
Relevant data shows that in 2021, the number of new Chinese medicine drug approvals will reach 12, far exceeding the sum of the number of approvals in recent years
.
Since the beginning of this year, there have also been news that a number of new Chinese medicines have been approved for marketing
.
For example, on February 28, Yunnan Baiyao declared a new class 1 traditional Chinese medicine drug "Quansanqi Tablets", which was approved by the State Food and Drug Administration to carry out clinical trials for chest tightness and heartache caused by cardiac stasis
.
It is reported that the drug is the first type 1 new drug of traditional Chinese medicine approved by Yunnan Baiyao after the reform of traditional Chinese medicine registration and classification, and the second new drug of traditional Chinese medicine syndrome approved by Yunnan Baiyao after Fu Qiguben ointment with independent intellectual property rights
.
At present, in addition to the continuous approval of new traditional Chinese medicines, a large number of pharmaceutical companies are enthusiastic about innovation, and many listed traditional Chinese medicine companies have indicated that they will increase their research and development efforts and investment in new traditional Chinese medicines in the future
.
In this regard, analysts believe that the long-term growth of innovative traditional Chinese medicine drugs can be expected, and it is recommended to actively pay attention to innovative traditional Chinese medicine drug companies; in addition, upstream and downstream enterprises in the production chain are also worthy of attention
.
After all, the approval of a new drug is only a basic step, and subsequent related companies still need to face challenges in production, commercialization, and marketing
.
For example, in the production process, the input of corresponding equipment and the support of experienced talents are needed to ensure the stable operation of production
.
It is foreseeable that behind the "blowout" growth in the number of innovative Chinese medicine drugs, the field of traditional Chinese medicine pharmaceutical equipment may benefit
.
However, it should be noted that with the continuous improvement of the quality and curative effect requirements of traditional Chinese medicine and the stricter supervision, the process and control technology of traditional Chinese medicine extraction are also facing the challenge of upgrading.
.
For example, on the premise of ensuring the consistency of the dosage ratio of the decoction pieces and the extraction solvent, it is necessary to strengthen the research on the parameters of the industrialized preparation process, establish rigorous quality testing methods, and use more sophisticated testing instruments and pharmaceutical equipment to ensure the preparation extraction process is stable.
dry paste rate and index ingredient transfer rate
.
It is understood that in order to accelerate the innovative research on new Chinese medicines, China's pharmaceutical equipment industry has been continuously developing higher-quality Chinese medicine equipment and Chinese medicine pharmaceutical equipment to meet the needs of high-quality development of the modern Chinese medicine industry
.
At present, with the continuous development of science and technology and the continuous upgrading of pharmaceutical equipment companies, a number of intelligent Chinese medicine extraction equipment have appeared on the market, which can automatically control the extraction process through informatization and digitization, and realize the management information of the entire production process.
automation, equipment automation, and standardization of personnel operations
.
In general, with the continuous favorable policies, the approval and marketing of new Chinese medicines will be accelerated in the future, and the number of new Chinese medicines on the market may exceed 20 each year
.
In this context, for pharmaceutical companies, the use of modern science and technology to promote the modernization of traditional Chinese medicine and open up new paths for the inheritance, innovation and development of traditional Chinese medicine will become the main responsibility of development
.
For pharmaceutical machine companies, it is necessary to continuously build advanced pharmaceutical equipment to provide technical and equipment support for the traditional Chinese medicine pharmaceutical industry
.
Affected by this, it is expected that more high-tech intelligent and automated high-end equipment may be promising
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Affected by this, the market space of traditional Chinese medicine is being further opened up.
According to analysis and prediction, the traditional Chinese medicine market will exceed 1 trillion yuan in 2024.
The prospects are very promising
.
The enthusiasm for the research and development of innovative traditional Chinese medicine drugs is high, and a large number of enterprises will benefit
.
It is understood that with the support of a series of favorable policies, both the number of applications and the number of approvals for innovative Chinese medicines in China have increased significantly
.
Relevant data shows that in 2021, the number of new Chinese medicine drug approvals will reach 12, far exceeding the sum of the number of approvals in recent years
.
Since the beginning of this year, there have also been news that a number of new Chinese medicines have been approved for marketing
.
For example, on February 28, Yunnan Baiyao declared a new class 1 traditional Chinese medicine drug "Quansanqi Tablets", which was approved by the State Food and Drug Administration to carry out clinical trials for chest tightness and heartache caused by cardiac stasis
.
It is reported that the drug is the first type 1 new drug of traditional Chinese medicine approved by Yunnan Baiyao after the reform of traditional Chinese medicine registration and classification, and the second new drug of traditional Chinese medicine syndrome approved by Yunnan Baiyao after Fu Qiguben ointment with independent intellectual property rights
.
At present, in addition to the continuous approval of new traditional Chinese medicines, a large number of pharmaceutical companies are enthusiastic about innovation, and many listed traditional Chinese medicine companies have indicated that they will increase their research and development efforts and investment in new traditional Chinese medicines in the future
.
In this regard, analysts believe that the long-term growth of innovative traditional Chinese medicine drugs can be expected, and it is recommended to actively pay attention to innovative traditional Chinese medicine drug companies; in addition, upstream and downstream enterprises in the production chain are also worthy of attention
.
After all, the approval of a new drug is only a basic step, and subsequent related companies still need to face challenges in production, commercialization, and marketing
.
For example, in the production process, the input of corresponding equipment and the support of experienced talents are needed to ensure the stable operation of production
.
It is foreseeable that behind the "blowout" growth in the number of innovative Chinese medicine drugs, the field of traditional Chinese medicine pharmaceutical equipment may benefit
.
However, it should be noted that with the continuous improvement of the quality and curative effect requirements of traditional Chinese medicine and the stricter supervision, the process and control technology of traditional Chinese medicine extraction are also facing the challenge of upgrading.
.
For example, on the premise of ensuring the consistency of the dosage ratio of the decoction pieces and the extraction solvent, it is necessary to strengthen the research on the parameters of the industrialized preparation process, establish rigorous quality testing methods, and use more sophisticated testing instruments and pharmaceutical equipment to ensure the preparation extraction process is stable.
dry paste rate and index ingredient transfer rate
.
It is understood that in order to accelerate the innovative research on new Chinese medicines, China's pharmaceutical equipment industry has been continuously developing higher-quality Chinese medicine equipment and Chinese medicine pharmaceutical equipment to meet the needs of high-quality development of the modern Chinese medicine industry
.
At present, with the continuous development of science and technology and the continuous upgrading of pharmaceutical equipment companies, a number of intelligent Chinese medicine extraction equipment have appeared on the market, which can automatically control the extraction process through informatization and digitization, and realize the management information of the entire production process.
automation, equipment automation, and standardization of personnel operations
.
In general, with the continuous favorable policies, the approval and marketing of new Chinese medicines will be accelerated in the future, and the number of new Chinese medicines on the market may exceed 20 each year
.
In this context, for pharmaceutical companies, the use of modern science and technology to promote the modernization of traditional Chinese medicine and open up new paths for the inheritance, innovation and development of traditional Chinese medicine will become the main responsibility of development
.
For pharmaceutical machine companies, it is necessary to continuously build advanced pharmaceutical equipment to provide technical and equipment support for the traditional Chinese medicine pharmaceutical industry
.
Affected by this, it is expected that more high-tech intelligent and automated high-end equipment may be promising
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.